Hikal Ltd Falls 5.46% This Week: 3 Key Factors Behind the Downtrend

Jan 11 2026 03:00 PM IST
share
Share Via
Hikal Ltd’s stock declined by 5.46% over the week ending 9 January 2026, underperforming the Sensex which fell 2.62% in the same period. The pharmaceutical company faced sustained selling pressure amid deteriorating technical signals, fresh 52-week lows, and weak financial results, reflecting ongoing challenges in its sector and business fundamentals.




Key Events This Week


5 Jan: Stock opens at Rs.225.20, down 1.18% amid weak market sentiment


6 Jan: Intensified downtrend confirmed with technical indicators signalling bearish momentum


8 Jan: Stock hits 52-week low of Rs.217, reflecting financial and operational pressures


9 Jan: Further decline to new 52-week low of Rs.213.75, continuing the downtrend





Week Open
Rs.227.90

Week Close
Rs.215.45
-5.46%

Week High
Rs.225.20

vs Sensex
-2.84%



5 January 2026: Week Opens on a Weak Note


Hikal Ltd began the week at Rs.225.20, down 1.18% from the previous Friday’s close of Rs.227.90. The decline coincided with a modest 0.18% drop in the Sensex, signalling early weakness in the stock amid broader market softness. Trading volume was moderate at 9,332 shares, reflecting cautious investor sentiment. The stock’s price was already hovering near its recent lows, setting the tone for a challenging week ahead.



6 January 2026: Technical Indicators Signal Intensified Downtrend


On 6 January, Hikal’s share price fell further to Rs.223.10, a 0.93% decline on the day, while the Sensex dropped 0.19%. This day marked a significant shift as technical analysis revealed a more pronounced bearish trend. The stock traded below all key moving averages, confirming sustained selling pressure. Despite some mildly bullish weekly MACD signals, the monthly MACD and other momentum oscillators indicated a dominant downtrend. The stock’s proximity to its 52-week low of Rs.217.35 underscored the persistent negative momentum.




Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!



  • - Expert-scrutinized selection

  • - Already delivering results

  • - Monthly focused approach


Get Next Month's Pick →




7 January 2026: Marginal Recovery Amid Market Stability


The stock saw a slight uptick to Rs.223.25, gaining 0.07% on the day, while the Sensex edged up 0.03%. This minor recovery was insufficient to reverse the prevailing downtrend but indicated some short-term buying interest. Volume dipped to 8,839 shares, suggesting limited conviction behind the move. Technical oscillators remained mixed, with weekly momentum indicators showing faint bullishness but monthly trends still bearish.



8 January 2026: New 52-Week Low Highlights Financial Struggles


Hikal Ltd’s stock plunged to a fresh 52-week low of Rs.217, down 2.15% on the day, significantly underperforming the Nifty index which fell 1.01%. The decline reflected mounting concerns over the company’s deteriorating financial performance. The latest quarterly results revealed a 320.54% drop in earnings per share and a net loss after tax of Rs.34.90 crore. Operating profit contracted sharply, with a five-year CAGR decline of 16.24%. The company’s leverage remained high, with a debt to EBITDA ratio of 2.51 times and an operating profit to interest coverage ratio of just 0.48 times, signalling constrained financial flexibility.



9 January 2026: Continued Downtrend Extends Losses to 5.46% for the Week


The downtrend persisted as Hikal’s stock fell further to Rs.215.45, a 1.37% decline on the day and a new 52-week low of Rs.213.75 intraday. This marked a cumulative two-day drop of 3.87%. The stock underperformed its Pharmaceuticals & Biotechnology sector by 1.46%, emphasising relative weakness. Despite trading near its lowest levels in a year, valuation metrics such as an enterprise value to capital employed ratio of 1.8 suggested some discount relative to peers. However, the company’s weak profitability, modest return on equity of 8.00%, and low return on capital employed of 4.44% continued to weigh on investor confidence.




Holding Hikal Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!



  • - Peer comparison ready

  • - Superior options identified

  • - Cross market-cap analysis


Switch to Better Options →




















































Date Stock Price Day Change Sensex Day Change
2026-01-05 Rs.225.20 -1.18% 37,730.95 -0.18%
2026-01-06 Rs.223.10 -0.93% 37,657.70 -0.19%
2026-01-07 Rs.223.25 +0.07% 37,669.63 +0.03%
2026-01-08 Rs.218.45 -2.15% 37,137.33 -1.41%
2026-01-09 Rs.215.45 -1.37% 36,807.62 -0.89%



Key Takeaways


Bearish Technical Momentum: The stock’s consistent trading below all major moving averages and bearish monthly MACD signals confirm a dominant downtrend. Despite some weekly oscillators showing mild bullishness, the overall technical picture remains negative.


Financial Weakness: A sharp 320.54% decline in quarterly EPS and a net loss of Rs.34.90 crore highlight significant operational challenges. High leverage with a debt to EBITDA ratio of 2.51 times and low interest coverage ratio of 0.48 times further constrain financial flexibility.


Valuation Discount Amidst Risk: The enterprise value to capital employed ratio of 1.8 suggests the stock trades at a discount relative to peers. However, this valuation advantage is tempered by the company’s sustained profit contraction and weak returns on equity and capital employed.



Sector Underperformance: Hikal Ltd’s stock has underperformed both the Pharmaceuticals & Biotechnology sector and the broader market indices, with a one-year return of -42.16% compared to Sensex’s +8.30%. This highlights company-specific headwinds beyond general market weakness.



Ownership Stability: Promoter shareholding remains concentrated and stable, indicating no significant changes in corporate control despite the stock’s volatility.



Investors should note the prevailing negative sentiment and technical weakness, balanced against some valuation appeal. The stock’s performance this week underscores the challenges facing Hikal Ltd amid a difficult operating environment and financial strain.






{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Hikal Ltd falling/rising?
Jan 06 2026 02:16 AM IST
share
Share Via
Hikal Ltd is Rated Strong Sell
Jan 05 2026 10:11 AM IST
share
Share Via
Hikal Ltd is Rated Strong Sell
Dec 25 2025 12:57 PM IST
share
Share Via